The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease

Objectives: Behçet's disease (BD) is a systemic vasculitis. Since vascular endothelial dysfunction plays a prominent role in the pathogenesis of the disease, we considered angiogenic cytokines as an interesting target for investigation in BD. The aim of this study was to investigate the possible role of angiogenin, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD.

Design and Methods: Sixty five patients with BD and 21 healthy control subjects were included in the study. Serum angiogenin, bFGF and VEGF concentrations were determined by using in vitro enzyme immunoassay (ELISA) kits according to the manufacturer's instructions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Behçet's Disease Behcet Syndrome Cardiovascular Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Eye Diseases Genetic Diseases, Inborn Hereditary Autoinflammatory Diseases Mouth Diseases Panuveitis Skin Diseases Skin Diseases, Genetic Skin Diseases, Vascular Skin and Connective Tissue Diseases Stomatognathic Diseases Uveal Diseases Uveitis Uveitis, Anterior Vascular Diseases Vasculitis

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara University, Faculty of Medicine, Department of Ophthalmology

Ankara, 06620, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age between 18-65
fulfilling the international diagnostic criteria for Behçet's disease

Exclusion criteria

to have another systemic disease

Treatment and study plan

serum levels of angiogenin, bFGF, VEGF

Other

Behçet's patients

Primary outcomes

Serum levels of angiogenin in Behçet's patients with or without ocular involvement

Time frame: 1 year

The median serum angiogenin level was significantly higher in all patients with BD than controls (P=0.001). However there was no statistically significant difference between all patients and patients with or without ocular involvement. The mean serum bFGF and the median serum VEGF levels were higher in patients with ocular involvement than all patients, patients without ocular involvement and controls. But these differences did not reach statistical significance.

Secondary outcomes

Serum levels of bFGF in Behçet's patients with or without ocular involvement

Time frame: 1 year

Other outcomes

Serum levels of VEGF in Behçet's patients with or without ocular involvement

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Turkish Ophthalmology Society

Other

Registry information

Important dates

Study start: 2011
Primary completion: 2011
Study completion: 2012
First posted: Nov 2, 2012
Registry last updated: Nov 2, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed